Abstract In the United States, prostate cancer (PCa) is the most commonly diagnosed non-
cutaneous cancer in males and the second leading cause of cancer-related death for men …

Systemic treatment of advanced prostate cancer is initiated with androgen deprivation
therapy by gonadal testosterone depletion. Response durations are variable and tumors …

Prostate cancers that are progressing on medical and surgical therapies designed to ablate
the action of androgens continue to express androgen receptor (AR) and to depend on …

The androgen receptor (AR) signaling axis drives all stages of prostate cancer, including the
lethal, drug-resistant form of the disease termed castration-resistant prostate cancer (CRPC) …

Androgen deprivation is still the standard systemic therapy for metastatic prostate cancer
(PCa), but patients invariably relapse with a more aggressive form of PCa termed hormone …

Discoveries over the past decade suggest that castration-resistant prostate cancer (CRPC)
is sensitive, but not resistant to, further manipulation of the androgen–androgen receptor …

Androgen receptor (AR) is a steroid receptor transcriptional factor for testosterone and
dihydrotestosterone consisting of four main domains, the N-terminal domain, DNA-binding …

Few effective therapies exist for the treatment of castration-resistant prostate cancer (CRPC).
Recent evidence suggests that CRPC may be caused by augmented androgen/androgen …

The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in
prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth …

Androgen receptor (AR), a ligand-dependent nuclear transcription factor and a member of
steroid hormone receptor family, plays an important role in prostate organogenesis by …